ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

maralixibat

Also written as “Maralixibat”, “LUM001” and “LUM001 (Maralixibat)”.

Its studies are mostly in Alagille Syndrome · Cholestasis, progressive familial intrahepatic 1 · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary · Intrahepatic Cholestasis of Pregnancy, led by 2 companies.

Drug pageMaralixibat: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 17, 202521 company-led studies, 3 open or runningNext primary completion: Jan 12, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mirum Pharmaceuticalsits history only193 open or runningphase 4since Sep 17, 2025Jul 16, 2013Jan 12, 2029phase 2 · NCT07823127
Takeda20 open or runningphase 3since Sep 14, 2022Sep 14, 2022none ahead

Also a collaborator on its studies: Lumena Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2022First studies: 2 phase 3 studiesFirst studyNCT05543187, NCT05543174

TargetBeta

SLC10A2 →read by rule
“Ileal bile acid transporter inhibitor; Ileal bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A2

ProgramCompanyFurthest phaseStudies
linerixibatruleGlaxoSmithKlinephase 314

Studies

All 2 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05543187Cholestasis, progressive familial intrahepatic 1 · Japan3CompletedSep 4, 20235
NCT05543174Alagille Syndrome · Japan3CompletedOct 25, 20237

How it is read

Names in the registry

  • “Maralixibat”, 9 entries
  • “LUM001”, 5 entries
  • “LUM001 (Maralixibat)”, 4 entries
  • “TAK-625”, 2 entries
  • “Livmarli Oral Product”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.